HRP20191486T2 - Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze - Google Patents

Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze Download PDF

Info

Publication number
HRP20191486T2
HRP20191486T2 HRP20191486TT HRP20191486T HRP20191486T2 HR P20191486 T2 HRP20191486 T2 HR P20191486T2 HR P20191486T T HRP20191486T T HR P20191486TT HR P20191486 T HRP20191486 T HR P20191486T HR P20191486 T2 HRP20191486 T2 HR P20191486T2
Authority
HR
Croatia
Prior art keywords
fluoro
methoxy
chloro
hydroxypiperidin
fluorophenyl
Prior art date
Application number
HRP20191486TT
Other languages
English (en)
Croatian (hr)
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka UEMATSU
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori KANESHIGE
Yuya NAKAI
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191486(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20191486T1 publication Critical patent/HRP20191486T1/hr
Publication of HRP20191486T2 publication Critical patent/HRP20191486T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20191486TT 2014-08-28 2015-08-28 Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze HRP20191486T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
EP15763096.3A EP3186240B9 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
HRP20191486T1 HRP20191486T1 (hr) 2019-11-15
HRP20191486T2 true HRP20191486T2 (hr) 2021-09-17

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191486TT HRP20191486T2 (hr) 2014-08-28 2015-08-28 Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze

Country Status (29)

Country Link
US (2) US10053446B2 (OSRAM)
EP (1) EP3186240B9 (OSRAM)
JP (1) JP6625612B2 (OSRAM)
KR (1) KR102418413B1 (OSRAM)
CN (1) CN106795117B (OSRAM)
AP (1) AP2017009788A0 (OSRAM)
AR (1) AR101704A1 (OSRAM)
AU (1) AU2015307873B2 (OSRAM)
BR (1) BR112017003231B1 (OSRAM)
CA (1) CA2959478C (OSRAM)
CY (1) CY1122286T1 (OSRAM)
DK (1) DK3186240T3 (OSRAM)
EA (1) EA038414B1 (OSRAM)
ES (1) ES2743788T3 (OSRAM)
HR (1) HRP20191486T2 (OSRAM)
HU (1) HUE045025T2 (OSRAM)
IL (1) IL250484B (OSRAM)
LT (1) LT3186240T (OSRAM)
MX (1) MX2017002312A (OSRAM)
MY (1) MY189098A (OSRAM)
NZ (1) NZ729064A (OSRAM)
PH (1) PH12017500290B1 (OSRAM)
PL (1) PL3186240T3 (OSRAM)
PT (1) PT3186240T (OSRAM)
SG (1) SG11201700882XA (OSRAM)
SI (1) SI3186240T1 (OSRAM)
TW (1) TWI687409B (OSRAM)
WO (1) WO2016031255A1 (OSRAM)
ZA (1) ZA201700916B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
WO2017146246A1 (ja) * 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
US20210292333A1 (en) 2018-06-15 2021-09-23 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
EP4201407A4 (en) * 2020-08-19 2024-07-31 MitoImmune Therapeutics Inc. ANTIOXIDANT TARGETING MITOCHONDRIA AS AN AGENT FOR THE TREATMENT OF PATHOLOGICAL INFLAMMATION CAUSED BY MABC-R INFECTION
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
WO2005042542A1 (en) 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
WO2007099828A1 (ja) 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
EP2459570B1 (en) 2009-07-31 2014-12-24 Global Alliance For Tb Drug Development Nitroimidazooxazine analogues and their uses
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
WO2017146246A1 (ja) * 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体

Also Published As

Publication number Publication date
ES2743788T3 (es) 2020-02-20
AU2015307873A1 (en) 2017-03-09
MX2017002312A (es) 2017-05-08
AR101704A1 (es) 2017-01-04
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
DK3186240T3 (da) 2019-08-26
TW201609658A (zh) 2016-03-16
HRP20191486T1 (hr) 2019-11-15
MY189098A (en) 2022-01-25
HUE045025T2 (hu) 2019-12-30
EP3186240B1 (en) 2019-06-12
ZA201700916B (en) 2019-06-26
BR112017003231A2 (pt) 2017-11-28
AP2017009788A0 (en) 2017-02-28
JP6625612B2 (ja) 2019-12-25
CA2959478C (en) 2023-09-26
BR112017003231B1 (pt) 2022-10-11
SI3186240T1 (sl) 2019-10-30
KR102418413B1 (ko) 2022-07-06
PL3186240T3 (pl) 2020-03-31
KR20170043644A (ko) 2017-04-21
PH12017500290B1 (en) 2023-07-19
IL250484B (en) 2020-04-30
US10464926B2 (en) 2019-11-05
PT3186240T (pt) 2019-09-06
WO2016031255A1 (en) 2016-03-03
EP3186240B9 (en) 2019-12-04
PH12017500290A1 (en) 2017-06-28
AU2015307873B2 (en) 2020-01-16
NZ729064A (en) 2022-09-30
CN106795117B (zh) 2020-06-26
EA201790464A1 (ru) 2017-06-30
EP3186240A1 (en) 2017-07-05
TWI687409B (zh) 2020-03-11
JP2017525697A (ja) 2017-09-07
CA2959478A1 (en) 2016-03-03
CY1122286T1 (el) 2021-01-27
US20170253576A1 (en) 2017-09-07
IL250484A0 (en) 2017-03-30
CN106795117A (zh) 2017-05-31
SG11201700882XA (en) 2017-03-30
US10053446B2 (en) 2018-08-21
EA038414B1 (ru) 2021-08-25

Similar Documents

Publication Publication Date Title
ES2527467T3 (es) Nuevas bencenosulfonamidas como bloqueantes de canales de calcio
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
JP2011511790A5 (OSRAM)
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AR049139A1 (es) Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
MA34964B1 (fr) Dérivés de pipéridine pontés
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
AR049739A1 (es) Derivados de aril-piridina
IL276946B (en) Antiproliferative compounds and methods of use
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR046648A1 (es) 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli (adp-ribosa) polimerasa
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
JP2016506403A5 (OSRAM)
CO6220970A2 (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
MA29398B1 (fr) Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene.
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
RU2020105248A (ru) Новые соединения и их фармацевтические композиции для лечения фиброза
DK2868660T3 (da) Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa